Table 2.
AMPs of farm animal origin in clinical trials.
| AMPs | Source | Clinical Phase | Indication | Administration | Clinical Identifier |
|---|---|---|---|---|---|
| MBI-226Omignan | Indolicidin(Bovine) | Phase III | Prevention of local catheter site infection and colonization in patients with central venous catheters | Topical gel | NCT00231153 |
| CLS001Omignan | Phase III | Severe papulopustular rosacea | Topical gel | NCT02576860 | |
| MX942 (SGX942) | Phase III | Immunomodulation during oral mucositis | Intravenous infusion | NCT03237325 | |
| Omignan | Phase II | Seborrheic Dermatitis | Topical Gel | NCT03688971 | |
| IB-367Isegnan | Protegrin-1 Derivative | Phase III | Oral mucositis in the patient receiving radiation therapy for head and neck cancer | Oral solution | NCT00022373 |
| POL7080 | Protegrin-1Analog | Phase II | Non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection. | Intravenous infusion | NCT02096328 |